Kiran Mazumdar-Shaw

Chemify Announces $43 Million of Funding to Digitize Chemistry

Retrieved on: 
Wednesday, August 2, 2023
Biotechnology, Technology, Manufacturing, Health, Robotics, Other Science, Research, Software, Artificial Intelligence, Science, Chemicals, Plastics, University, Intelligence, Multimedia, Medicine, Chemistry, Drug discovery, AI, UK, Eos, Kiran Mazumdar-Shaw, Pharmaceutical industry, Fine chemical, Abcam

Professor Cronin’s pioneering research spans the digitization of chemistry including the use of artificial intelligence in chemistry to explore ‘chemical space’ - to access and create the trillions of possible combinations of natural elements.

Key Points: 
  • Professor Cronin’s pioneering research spans the digitization of chemistry including the use of artificial intelligence in chemistry to explore ‘chemical space’ - to access and create the trillions of possible combinations of natural elements.
  • With over $30 million invested in the foundational research behind Chemify, the team developed a new digital chemical approach to program chemistry.
  • Chemify’s vision is to build the infrastructure to digitize chemistry and enable the execution of chemical code for drug discovery, chemical synthesis, and materials discovery.
  • Chemify is creating a digital chemical future where the access to important molecules, drugs, and new materials, currently unimaginable, are instantly accessible.

Viatris Inc. and Biocon Biologics Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes

Retrieved on: 
Thursday, July 29, 2021
Life sciences, Biology, Branches of biology, Biotechnology, Peptide hormones, Recombinant proteins, Biocon, Biosimilar, Insulin glargine, Kiran Mazumdar-Shaw, Insulin, Biopharmaceutical

The company is eligible to have exclusivity for 12 months before the FDA can approve another biosimilar interchangeable to Lantus.

Key Points: 
  • The company is eligible to have exclusivity for 12 months before the FDA can approve another biosimilar interchangeable to Lantus.
  • Semglee is indicated to control high blood sugar in adults with Type 2 diabetes and adults and pediatric patients with Type 1 diabetes.
  • Biocon Biologics, Executive Chairperson, Kiran Mazumdar-Shaw said: "We are extremely proud to be the first to obtain approval of an interchangeable Biosimilar product in the U.S.
  • This will allow pharmacy level substitution and thereby provide convenient and affordable access to Semglee, a quality Biosimilar Insulin Glargine."

Adagio Therapeutics Partners with Biocon Biologics to Bring Potent and Broadly Neutralizing COVID-19 Antibody Treatment to Patients in India and Select Emerging Markets

Retrieved on: 
Monday, July 26, 2021
Health, Infectious diseases, Other Health, General Health, Pharmaceutical, Biotechnology, Life sciences, Biotechnology, Articles, Biocon, Specialty drugs, Biopharmaceutical, Biosimilar, Kiran Mazumdar-Shaw

Biocon Biologics Ltd. is a fully integrated biosimilars company and a subsidiary of Biocon Ltd., a global biopharmaceuticals company, (BSE code: 532523, NSE: BIOCON).

Key Points: 
  • Biocon Biologics Ltd. is a fully integrated biosimilars company and a subsidiary of Biocon Ltd., a global biopharmaceuticals company, (BSE code: 532523, NSE: BIOCON).
  • Under the terms of the agreement, Adagio will provide Biocon with materials and know-how to manufacture and commercialize an antibody treatment based on ADG20 in India and additional select emerging markets.
  • ADG20, Adagios lead product candidate, is designed to be a potent, long-acting and broadly neutralizing antibody for both the treatment and prevention of COVID-19 as either a single or combination agent.
  • The partnership provides Biocon rights to manufacture and commercialize an antibody treatment in India and additional select emerging markets based on the commercial process developed for ADG20.

PureTech Appoints Kiran Mazumdar-Shaw, Founder and Chairperson of a Leading Global Biopharmaceutical Company, to Board of Directors

Retrieved on: 
Thursday, October 1, 2020
Biotechnology, Pharmaceutical, Health, Oncology, Economy of India, Biocon, Companies based in Bangalore, Kiran Mazumdar-Shaw, Businesspeople, Science and technology in India, Kiran, Trailblazer

Ms. Shaw is an industry trailblazer who has spent her career surpassing societal expectations as the founder and chairperson of Indias largest and a leading global biopharmaceutical company, Biocon Limited.

Key Points: 
  • Ms. Shaw is an industry trailblazer who has spent her career surpassing societal expectations as the founder and chairperson of Indias largest and a leading global biopharmaceutical company, Biocon Limited.
  • View the full release here: https://www.businesswire.com/news/home/20200930005976/en/
    PureTech announced the appointment of biotech entrepreneur Kiran Mazumdar-Shaw to its board of directors.
  • She also has a keen interest in improving the health of people around the world, said Christopher Viehbacher, chairman of PureTechs board of directors.
  • Kiran brings a wealth of experience and knowledge to PureTechs board as we enter this next exciting chapter of growth.

Mylan and Biocon Announce U.S. FDA Approval of Semglee™ (insulin glargine injection)

Retrieved on: 
Thursday, June 11, 2020
Life sciences, Articles, Eli Lilly and Company, Peptide hormones, Recombinant proteins, RTT, Biotechnology, Biocon, Kiran Mazumdar-Shaw, Biosimilar, Mylan, Insulin

I would like to recognize the extraordinary work and leadership of both Mylan and Biocon's scientific and regulatory teams for this achievement.

Key Points: 
  • I would like to recognize the extraordinary work and leadership of both Mylan and Biocon's scientific and regulatory teams for this achievement.
  • Semglee represents another component to our global biosimilars franchise approach in advancing access to complex medicines."
  • Kiran Mazumdar Shaw, Chairperson, Biocon,said: "The approval of our insulin glargine by the U.S. FDA marks the culmination of a long journey.
  • Mylan and Biocon Biologic's insulin glargine has received regulatory approval in more than 45 countries around the world and is the third product approved by FDA through the Mylan-Biocon Biologics collaboration.

Dr. Kiran Mazumdar-Shaw from India named EY World Entrepreneur Of The Year™ 2020

Retrieved on: 
Thursday, June 4, 2020
Economy of India, Companies, Kiran Mazumdar-Shaw, Biocon, Indian people, Ernst & Young, Kiran, Mazumdar

LONDON, June 4, 2020 /PRNewswire/ --Dr. Kiran Mazumdar-Shaw, Executive Chairperson of India-based Biocon Limited, was this evening named EY World Entrepreneur Of The Year 2020 at a ground-breaking, virtual award ceremony.

Key Points: 
  • LONDON, June 4, 2020 /PRNewswire/ --Dr. Kiran Mazumdar-Shaw, Executive Chairperson of India-based Biocon Limited, was this evening named EY World Entrepreneur Of The Year 2020 at a ground-breaking, virtual award ceremony.
  • In the award's 20-year history, Kiran becomes the third EY World Entrepreneur Of The Year Award winner from India.
  • It's important that we use the platform of EY World Entrepreneur Of The Year to encourage more women to participate in entrepreneurial pursuits.
  • Winners go on to compete for the EY World Entrepreneur Of The Year title.

Dr. Kiran Mazumdar-Shaw from India named EY World Entrepreneur Of The Year™ 2020

Retrieved on: 
Thursday, June 4, 2020
Economy of India, Companies, Kiran Mazumdar-Shaw, Biocon, Indian people, Ernst & Young, Kiran, Mazumdar

LONDON, June 4, 2020 /PRNewswire/ --Dr. Kiran Mazumdar-Shaw, Executive Chairperson of India-based Biocon Limited, was this evening named EY World Entrepreneur Of The Year 2020 at a ground-breaking, virtual award ceremony.

Key Points: 
  • LONDON, June 4, 2020 /PRNewswire/ --Dr. Kiran Mazumdar-Shaw, Executive Chairperson of India-based Biocon Limited, was this evening named EY World Entrepreneur Of The Year 2020 at a ground-breaking, virtual award ceremony.
  • In the award's 20-year history, Kiran becomes the third EY World Entrepreneur Of The Year Award winner from India.
  • It's important that we use the platform of EY World Entrepreneur Of The Year to encourage more women to participate in entrepreneurial pursuits.
  • Winners go on to compete for the EY World Entrepreneur Of The Year title.